Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IT-101 Maintenance in Platinum-Sensitive Ovarian Cancer
NCT00753740Phase 2Withdrawn
- Sponsor
- Lumos Pharma, Inc.
- Start
- Sep 2008
- Primary completion
- Oct 2009
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CRLX101 in ovarian cancer, sponsored by Lumos Pharma, Inc.. Planned start Sep 2008; status: withdrawn.
02
Drugs
CRLX101
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00753740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753740.